These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28875531)

  • 1. Pathogen reduction of whole blood: utility and feasibility.
    Allain JP; Goodrich R
    Transfus Med; 2017 Oct; 27 Suppl 5():320-326. PubMed ID: 28875531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on pathogen reduction technology for therapeutic plasma: an overview.
    Solheim BG; Seghatchian J
    Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries.
    Drew VJ; Barro L; Seghatchian J; Burnouf T
    Blood Transfus; 2017 Oct; 15(6):512-521. PubMed ID: 28488960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Whole Blood With Riboflavin and UV Light: Impact on Malaria Parasite Viability and Whole Blood Storage.
    Owusu-Ofori S; Kusi J; Owusu-Ofori A; Freimanis G; Olver C; Martinez CR; Wilkinson S; Mundt JM; Keil SD; Goodrich RP; Allain JP
    Shock; 2015 Aug; 44 Suppl 1(Suppl 1):33-8. PubMed ID: 25423125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology.
    Yonemura S; Doane S; Keil S; Goodrich R; Pidcoke H; Cardoso M
    Blood Transfus; 2017 Jul; 15(4):357-364. PubMed ID: 28665269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogen Inactivation Technologies: The Advent of Pathogen-Reduced Blood Components to Reduce Blood Safety Risk.
    Devine DV; Schubert P
    Hematol Oncol Clin North Am; 2016 Jun; 30(3):609-17. PubMed ID: 27112999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Mirasol Evaluation of Reduction in Infections Trial (MERIT): study protocol for a randomized controlled clinical trial.
    Kasirye R; Hume HA; Bloch EM; Lubega I; Kyeyune D; Shrestha R; Ddungu H; Musana HW; Dhabangi A; Ouma J; Eroju P; de Lange T; Tartakovsky M; White JL; Kakura C; Fowler MG; Musoke P; Nolan M; Grabowski MK; Moulton LH; Stramer SL; Whitby D; Zimmerman PA; Wabwire D; Kajja I; McCullough J; Goodrich R; Quinn TC; Cortes R; Ness PM; Tobian AAR
    Trials; 2022 Apr; 23(1):257. PubMed ID: 35379302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogen inactivation: emerging indications.
    Kleinman S
    Curr Opin Hematol; 2015 Nov; 22(6):547-53. PubMed ID: 26390164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxygen removal during pathogen inactivation with riboflavin and UV light preserves protein function in plasma for transfusion.
    Feys HB; Van Aelst B; Devreese K; Devloo R; Coene J; Vandekerckhove P; Compernolle V
    Vox Sang; 2014 May; 106(4):307-15. PubMed ID: 24460692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highlights of PBTI Coimbra Conference on PRT of Plasma & Current Opinions on Pathogen Reduction Treatment of Blood Components.
    de Sousa G; Seghatchian J
    Transfus Apher Sci; 2015 Apr; 52(2):228-32. PubMed ID: 25770045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multilayer-strategy to enhance optimal safety of the blood supply: The role of pathogen inactivation for optimizing recipient safety and helping health care cost containment: Moderator views.
    Seghatchian J
    Transfus Apher Sci; 2015 Apr; 52(2):233-6. PubMed ID: 25748230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion-transmitted bacterial strains.
    Schmidt M; Hourfar MK; Sireis W; Pfeiffer U; Göttig S; Kempf VA; McDonald CP; Seifried E
    Transfusion; 2015 Sep; 55(9):2104-12. PubMed ID: 26013691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogen inactivation: coming of age.
    Lozano M; Cid J
    Curr Opin Hematol; 2013 Nov; 20(6):540-5. PubMed ID: 24104416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogen reduction of blood components.
    Solheim BG
    Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover.
    Johnson L; Winter KM; Reid S; Hartkopf-Theis T; Marschner S; Goodrich RP; Marks DC
    Vox Sang; 2011 Oct; 101(3):208-14. PubMed ID: 21492184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis platelets.
    Mastroianni MA; Llohn AH; Akkök ÇA; Skogheim R; Ødegaard ER; Nybruket MJ; Flesland A; Mousavi SA
    Transfus Apher Sci; 2013 Oct; 49(2):285-90. PubMed ID: 23820429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the use of pathogen-reduced human plasma and platelet concentrates.
    Seltsam A; Müller TH
    Br J Haematol; 2013 Aug; 162(4):442-54. PubMed ID: 23710899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Robust inactivation of Plasmodium falciparum in red blood cell concentrates using amustaline and glutathione pathogen reduction.
    Sow C; Bouissou A; Girard YA; Singh GB; Bounaadja L; Payrat JM; Haas D; Isola H; Lanteri MC; Bringmann P; Grellier P
    Transfusion; 2022 May; 62(5):1073-1083. PubMed ID: 35385146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop.
    Klein HG; Glynn SA; Ness PM; Blajchman MA;
    Transfusion; 2009 Jun; 49(6):1262-8. PubMed ID: 19392769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products.
    Goodrich RP; Doane S; Reddy HL
    Biologicals; 2010 Jan; 38(1):20-30. PubMed ID: 20093041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.